ArticleClinical and experimental immunology2007
Vasoactive intestinal polypeptide enhances oral tolerance by regulating both cellular and humoral immune responses.
Article in Clinical and experimental immunology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 15 citations in OpenAlex.
- Ferroptosis in the Lacrimal Gland Is Involved in Dry Eye Syndrome Induced by Corneal Nerve Severing.Investigative ophthalmology & visual science · 2023Article
- Maternal atopy and offspring epigenome-wide methylation signature.Epigenetics · 2021Article
- Neuropeptides and lymphocyte populations in the porcine ileum and ileocecal lymph nodes during postnatal life.PloS one · 2018Article
- Glycoprotein A33 deficiency: a new mouse model of impaired intestinal epithelial barrier function and inflammatory disease.Disease models & mechanisms · 2015Article
- Oral gene application using chitosan-DNA nanoparticles induces transferable tolerance.Clinical and vaccine immunology : CVI · 2012Article
- VIP Regulates the Development & Proliferation of Treg in vivo in spleen.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2011Article
- The role of vasoactive intestinal peptide (VIP) in megakaryocyte proliferation.Journal of molecular neuroscience : MN · 2009Article
- Allergy and the gastrointestinal system.Clinical and experimental immunology · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vasoactive intestinal polypeptide (VIP) is an important signal molecule of the neuroendocrine-immune network. In the immune system, VIP has been found to act as an endogenous anti-inflammatory mediator. In the current study, it was found that VIP administration regulated oral tolerance by inhibiting both cellular and humoral responses. Compared with vehicle-treated mice, mice treated with VIP during the development of ovalbumin (OVA)-induced oral tolerance exhibited the least delayed-type hypersensitivity (DTH), showed profoundly reduced proliferative capacity and produced less interferon (IFN)-gamma, interleukin (IL)-6, IL-5, IL-10 and interferon-inducible protein (IP-10). IgA-secreting cells in the gut as well as OVA-specific IgG and other isotypes levels in plasma were inhibited significantly after VIP-treatment. The VPAC2 receptor may be involved in VIP-mediated oral tolerance enhancement. Taken together, these results suggest that VIP enhanced oral tolerance via regulating both cellular and humoral responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.